Yes, and nail Rosi to the bench. Let me skate out of the way for the first goal. Sheesh. Classic game. Period. The crowd sins the anthem? Still laughing on that one. Bring home 3-0 on Sunday
OT- "Hawks really showed something last night." that's how hockey is played by champions! now, if we can just get Bickell to show up!…i'll be there on sunday.
He must be Asian. I do not have a clue what he is talking about.
Darling was lights out in relief. Hawks really showed something last night.
A phase 1/2 trial completed recruitment back in Feb. 2015.
Run by Mundipharma Ltd.
First and two-phase clinical trials of Forodesine intended for the Japanese relapsed or refractory peripheral T-cell lymphoma (PTCL) patients
Is a Japanese relapsed or refractory peripheral T-cell lymphoma patients interest to examine pharmacokinetics of Forodesine, safety, and efficacy.
The first phase portion: safety and pharmacokinetics
second phase portion: efficacy, safety, and pharmacokinetics
Patient recruitment situation Call for Participation End - test ongoing
February 17, 2015 revision
Forodesine has been granted Orphan Drug status by the FDA for three indications: T-cell non-Hodgkin's lymphoma, including CTCL; CLL and related leukemias including T-cell prolymphocytic leukemia, adult T-cell leukemia, and hairy cell leukemia; and for treatment of B-ALL. The FDA has also granted “fast track” status to the development of forodesine for the treatment of relapsed or refractory T-cell leukemia, and Special Protocol Assessment (SPA) from the FDA for forodesine to conduct a pivotal clinical trial in CTCL with an oral formulation.
In November 2011, BioCryst and Mundipharma amended their 2006 licensing agreement to grant Mundipharma exclusive worldwide rights to develop and commercialize forodesine in the field of oncology.
Looks like HHS is getting ready to order antivirals April 8 FBO
April 8 Notice of Intent to Sole Source Contract 1 year plus 4 years of options for tamiflu
Added: Apr 08, 2015 3:26 pm
The Department of Homeland Security (DHS), Office of Procurement Operations (OPO), intends to issue a sole source, firm-fixed price contract under the authority of FAR 6.302-1, "Only one responsible source and no other supplies or services will satisfy agency requirements." The Government intends to award to Genentech USA, Inc. at 1 DNA Way, South San Francisco, CA 94080 for the antiviral medicine Oseltamivir (trade name Tamiflu).
DHS, Office of Health Affairs (OHA), requires this antiviral medicine for the DHS Antiviral Stockpile for pandemic and avian influenza preparedness. The stockpile is needed in order to have a readily available supply of medicine to protect DHS personnel in the event of a pandemic to ensure the continuity of its essential services and overall critical mission. The medicine must be approved by the Food and Drug Administration and demonstrated by the Centers for Disease Control to be effective in treating Influenza A, H1N1 Influenza and H5N1 Avian Influenza. Market research has shown that no other known contractors presently exist who could get the necessary CDC/FDA approvals to produce the product in sufficient quantities and deliver it in time to meet the current requirement.
hope things are going well. I guess I'll leave you guys to buy this company based on what? IDK.
With the efficacy of 4161 coming in lower than we expected and reduced pricing and expectations in the Peramivir program, I don't get it. Good luck.
Because their mouths holding banana creamom . Hedge seeing middle number ) 1 (
you like numbers jack? there is a 100% chance that i'll drink only 1 beer watching the Blackhawks beat the Predators game tonight. of course, the first six don't count, (pre determined parameters) and no one gets to count the empties in the garbage can….
"How much one can pump this".... niiiiiice.
Sentiment: Strong Buy
Never turn down $200M offering at a premium. Wow.
Husky.. the only shot BCRX has is the 2nd Gen trials.
4161 just isn't effective enough.
"DYAX knows they're going to be required to do a much tougher trail"
And a tougher TRIAL...which will make it a tougher "trail" for DYAX.
On the other hand, 4161 is coming down the mountain from a trial treating patients with over 70 attacks a year with a PH 2 / 3 trial with an easier patient population who have more "gas in the tank". Positive results = high probability.
thanks jacko! you helped me figure out why DYAX hurried their trial…that 230 million in cash is all their going to get for dx2930.
"what are they going to do with 4161" turn that question around jacko. what is DYAX going to do when our trial shows similar results at the EOY? answer: they just did it. they got cash.
DYAX knows they're going to be required to do a much tougher trail, you know, like one that's peer reviewed, and the trial parameters are much tougher. the trial starts the second that needle goes in the arm jacko, not 8 days later…ouch!
That huge powerful short lobby have done their worst but she is hanging strong. Next catalyst and you boogers are toast. The last part of March was spent in the low "8s" but the 3/30 short number had only dropped to 12.3 Million. I reckon you missed your exit fellas (least I hope so). "Stockpile Stockpile Stockpile..."